Keywords
Whole-brain radiotherapy
Supplemental precision radiotherapy
Therapeutic efficacy
Submitted : 2024-02-28
Accepted : 2024-03-14
Published : 2024-03-29
Abstract
Objective: To investigate the efficacy of whole-brain radiotherapy combined with supplemental precision radiotherapy compared to whole-brain radiotherapy alone for brain metastasis. Methods: Twenty-six cases of patients with brain metastasis were observed from January 2020 to June 2023. Thirteen cases each were randomly assigned to the observation group and the control group. The patients in the observation group received whole-brain radiotherapy combined with supplemental precision radiotherapy, while those in the control group received only whole-brain radiotherapy. Results: Comparing the quality of life scores between the two groups, the data from the observation group was significantly superior (P < 0.05). The survival rate of the observation group was higher than that of the control group, and their survival time was longer (P < 0.05). Additionally, compared with the control group, the observation group exhibited lower levels of various serum tumor factors after treatment (P < 0.05). Conclusion: Whole-brain radiotherapy combined with supplemental precision radiotherapy demonstrates improved clinical efficacy, prolonged survival time, and enhanced quality of life for patients with brain metastasis. These findings warrant further study and promotion.
References
Wang S, Guo D, 2022, Whole-Brain Radiotherapy Combined with Supplemental Precision Radiotherapy in Patients with Lung Cancer Brain Metastases. Chinese Journal of Physician Advancement, 45(4): 319–322.
Xu L, Chen Y, Wang M, 2022, Meta-Analysis of the Efficacy and Safety of Radiotherapy Combined with Immunotherapy for Lung Cancer Brain Metastases. Chinese Journal of Lung Cancer, 25(10): 715–722.
Li D, Yue C, Hu Y, et al., 2022, Efficacy and Correlation between Gene Polymorphisms at the VEGFR2-V297? Locus and Bevacizumab Combined with Whole-Brain Radiotherapy in Patients with Non-Small Cell Lung Cancer with Brain Metastases. Journal of Xuzhou Medical University, 42(4): 248–254.
Takayama Y, Yano J, Seike R, et al., 2022, Efficacy of Chemoimmunotherapy in NSCLC Patients with Brain Metastasis With or Without Prior Brain Radiotherapy. Anticancer Res, 42(10): 4805–4812. https://doi.org/10.21873/ anticanres.15985
Gu X, Chen R, Gong Q, et al., 2022, Effects of Stereotactic Whole-Brain Radiation Therapy Combined with Thalidomide on Near- and Long-Term Efficacy and Neurocognitive Function of Lung Adenocarcinoma Brain Metastases. China Medical Equipment, 19(3): 67–70.
Zhang J, Xue J, Zhang Z, et al., 2022, Clinical Efficacy of Whole-Brain Radiation Therapy Combined with Radio- Wave Knife for Multiple Brain Metastases and Its Effect on Patients’ Self-Care Ability. Shanxi Medical Journal, 51(8): 843–845.
Wang Z, Jiang Y, Zhu Q, et al., 2023, Prognosis of Non-Small Cell Lung Cancer Brain Metastasis Treated with Whole-Brain Radiotherapy Combined with Targeted Therapy and Its Effect on Patients’ Serum CEA Levels. Journal of Practical Cancer, 38(12): 1985–1988.
Gao H, Huang F, Wang H, et al., 2022, Correlation Between EGFR Mutation and the Efficacy of Temozolomide Combined with IGRT Large Segmental Radiation Therapy for Brain Metastases of Non-Small Cell Lung Cancer. Modern Biomedical Progress, 22(16): 3081–3085.
Yang H, Bai Y, Wei S, et al., 2022, Clinical Efficacy of Bevacizumab Combined with Radiotherapy in the Treatment of Brain Metastases from Lung Cancer and Its Effect on Patients’ Immune Function and Tumor Markers. Cancer Progress, 20(18): 1892–1895 + 1898.
Hu H, Tang C, Xie Y, et al., 2023, Therapeutic Effect of Radiotherapy Combined with Apatinib and Capecitabine in Patients with Triple-Negative Breast Cancer Brain Metastases. Chinese Contemporary Medicine, 30(29): 79–82.
Liang D, Zhang Y, Su T, et al., 2023, Efficacy and Safety of Fractionated Stereotactic Radiotherapy and Synchronized Chemotherapy Combined with Bevacizumab in the Treatment of Brain Metastasis of Lung Cancer. Zhongnan Pharmacology, 21(3): 823–827.